[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@masonat7 Avatar @masonat7 Mason

Mason posts on X about $nams, $amgn, $5b, amgn the most. They currently have XX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence stocks XXXX% finance XXXX%

Social topic influence $nams #4, $amgn 7.14%, $5b 7.14%, amgn 7.14%, $espr 7.14%, approved 7.14%, insurance 7.14%, combo 7.14%, drugs XXXX%

Top accounts mentioned or mentioned by @plainyogurt21 @rohitsjhawar @persimmonti @snupsnus @andrearilli @inshatters1 @planetoptimism @bowtiedbiotech @humbleanalysis @pcmbio @mechapreneur @alexberenson @kalshi @pcm_bio @a_a_free @_oliverventure @marion436842126

Top assets mentioned NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Amgen, Inc. (AMGN)

Top Social Posts #

Top posts by engagements in the last XX hours

"@PersimmonTI You think $AMGN would pay $5B+ for $NAMS after they originally sold off obicetrapib to NAMS for much less"
X Link @masonat7 2025-10-13T18:37Z XX followers, 4799 engagements

"$NAMS reminder that obicetrapib is not like other CETP inhibitors. Every other CETPi increased hs-CRP. Obicetrapib appears to modestly decrease hs-CRP"
X Link @masonat7 2025-10-13T16:45Z XX followers, XXX engagements

"@SnupSnus @PCM_bio @PersimmonTI There's going to be a big push to treat lp(a) if/when these lp(a) drugs get approved but insurance might only cover for 150nmol (similar to trial population) even though risk starts to increase at 50nmol. $NAMS is studying combo with repatha on lp(a) in the 50-150 range"
X Link @masonat7 2025-10-14T20:55Z XX followers, XXX engagements